Dosing & Uses
Multiple Myeloma
Pending FDA approval for stem cell mobilization (in addition to G-CSF) for autologous bone marrow transplantation in patients with multiple myeloma
Next:
Pharmacology
Mechanism of Action
CXCR4 inhibitor; CXCR4 controls mobilization and trafficking of hematopoietic stem cells (HSCs) through signaling pathways CXCL12 in bone marrow stromal cells binds to CXCR4 on HSCs and retain them in the bone marrow
Motixafortide blocks this interaction between CXCL12 ligand and CXCR4, which leads to stem cell mobilization to the peripheral blood for collection by apheresis and storage for autologous transplantation
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
